KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice (Q33759960)

29 July 2017

title

KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice (English)

1 reference

29 July 2017

1 reference

1 reference

4

Bengt Glimelius

1 reference

29 July 2017

2

Karolina Edlund

1 reference

29 July 2017

Magnus Sundström

1

1 reference

29 July 2017

Monica Lindell

3

1 reference

29 July 2017

Helgi Birgisson

5

1 reference

29 July 2017

Patrick Micke

6

1 reference

29 July 2017

Johan Botling

7

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

29 July 2017

1 reference

29 July 2017

volume

10

1 reference

29 July 2017

page(s)

660

1 reference

Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Fast simultaneous detection of K-RAS mutations in colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Recurrent KRAS codon 146 mutations in human colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

A high frequency of sequence alterations is due to formalin fixation of archival specimens

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

A sequencing method based on real-time pyrophosphate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Biological and biochemical properties of human rasH genes mutated at codon 61.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

ras oncogenes in human cancer: a review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002357

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-660

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-660

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-660

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-660

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-660

Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-660

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-660

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-660

Prevalence of ras gene mutations in human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-660

K-RAS-2 gene mutations as predictors of metachronous colorectal adenomas

21 January 2018

1 reference

12 December 2020

Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component

1 reference

12 December 2020

Relationship between genetic alterations and prognosis in sporadic colorectal cancer.

1 reference

12 December 2020

K-ras mutation detection in colorectal cancer using the Pyrosequencing technique

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-10-660

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference